Earlier, we identified a nucleoside analog named ARC (4-amino-6-hydrazino-7-b-D-ribofuranosyl-7H-pyrrolo[2,3-d]-pyrimidine-5-carboxamide), which is a CDK9/transcriptional inhibitor. 1 We and others showed that ARC selectively induced potent apoptosis in neuroblastoma, 2 melanoma 3 and other cancer cells, 4, 5 whereas it did not induce apoptosis in normal cells. In addition, ARC showed strong antiangiogenic activity in vitro.
1 ARC-induced apoptosis correlated with suppression of labile antiapoptotic protein Mcl-1, [2] [3] [4] and Mcl-1 overexpression protected melanoma and neuroblastoma cells from ARCinduced apoptosis. 2, 3 Abbott laboratories (Abbott Park, IL, USA) introduced Bcl-2/Bcl-X L inhibitor ABT-737 that competes with BAD for docking to the hydrophobic groove of Bcl-2 and augments Bax and Bak activation. 6 ABT-737 does not inhibit Mcl-1, and cancer cells with high levels of Mcl-1 are resistant to ABT-737. 6 Downregulation of Mcl-1 by short hairpin RNA significantly increased ABT-737-induced apoptosis. 7 In this paper, we show that ARC induces potent apoptosis in human leukemia cells and that combination of sub-apoptotic (nanomolar) concentrations of ARC and ABT-737 stimulates very robust cell death in leukemia cell lines.
To evaluate the effect of ARC on leukemia cells, we performed a growth inhibition assay on myeloid leukemia cell lines, U937, HL-60 and NB4, and on T-lymphoblastic leukemia cell line CEM. The cells were treated with different doses of ARC for 48 h and the cell number was counted in a Coulter Counter (Beckman Coulter Inc. Brea, CA, USA). The cell lines CEM, HL-60, NB4 and U937 displayed IC 50 s of 323, 157, 233 and 187 nM, respectively (Figure 1a) , implying that 50% of cell death of these cells is achieved in low nanomolar concentrations. To determine whether ARC induces apoptosis in leukemia cells, we treated these cells for 24 or 48 h with ARC, and apoptosis was assessed by the appearance of caspase-3 cleavage after immunoblotting. As shown in Figure 1b , 1-5 mM of ARC induced caspase-3 cleavage in all leukemia cell lines at 24 h, and 0.2-0.5 mM of ARC was sufficient to induce caspase-3 cleavage in HL60 and U937 cells after 48 h of treatment ( Figure 1b ). As we reported previously for a variety of cell types, 2-4 treatment with ARC led to apoptosis and attenuated the expression of antiapoptotic Mcl-1, but not that of antiapoptotic Bcl-2 protein in leukemia cell lines (Figure 1b) .
Two distinct pathways leading to cell death have been identified. First, the extrinsic pathway is initiated by death receptors, and second, the intrinsic pathway is initiated by the disruption of the mitochondrial membrane and accompanied by the release of cytochrome c. We found that ARC induces efficient apoptosis in leukemia cells after inhibition of caspase-8 (Figure 1c ), suggesting that it induces intrinsic apoptosis. To confirm the fact that ARC-induced apoptosis in leukemia cells is linked to mitochondrial membrane depolarization, we treated CEM, HL-60, NB4 and U937 leukemia cells with either dimethyl sulfoxide or 1 mM of ARC. After 24 h, cells were loaded with TMRE (tetramethylrhodamine ethyl ester), a mitochondrial membrane potential indicator and sorted by fluorescenceactivated cell sorting (FACS) analysis ( Figure 1d ). As shown in the Figure 1d , ARC treatment of leukemia cell lines led to a loss of mitochondrial membrane potential, as indicated by the shift to the left of the peak of TMRE fluorescence. These data suggest that administration of ARC promotes early mitochondrial damage in leukemia cells and they undergo ARC-induced apoptosis by the intrinsic pathway.
To further characterize the ability of ARC to induce apoptosis in leukemia cells, we examined how ARC affects TMRE and Annexin V-phycoerythrin (PE) (marker of apoptosis) staining in the presence and the absence of the pan-caspase inhibitor Z-VAD-FMK and caspase-2 inhibitor Z-VDVAD-FMK. First, we studied whether an inhibitor of caspase-2 (Z-VDVAD-FMK) or a pan-caspase inhibitor (Z-VAD-FMK) can protect U937 cells from ARC-induced mitochondrial injury by TMRE staining. As shown in Figure 1e , the pan-caspase inhibitor reversed ARCinduced mitochondrial depolarization, whereas caspase-2 inhibitor had no effect. Furthermore, using Annexin V-PE staining followed by FACS analysis we found that the pancaspase inhibitor protected the U9937 cells from ARC-induced apoptosis, whereas caspase-2 inhibitor did not ( Figure 1f As we showed earlier that Z-VAD-FMK protected against mitochondrial injury and apoptosis (Figures 1e and f) , we decided to test whether this pan-caspase inhibitor may reverse ARC-induced downregulation of Mcl-1 (Figure 2d ). When we found that Z-VAD-FMK abolished the downregulation of Mcl-1 protein by ARC (Figure 2d) , we explored the notion whether this inhibition occurs at mRNA level and whether it is specific for Mcl-1. We treated U937 cells with ARC alone, Z-VAD-FMK alone and with both the drugs for 8 h, extracted total RNA and measured mRNA levels for mcl-1, p21, hdm-2 and survivin by quantitative real-time reverse transcriptase-PCR (Figure 2e ). We found that Z-VAD-FMK specifically inhibited the downregulation of mcl-1 mRNA by ARC, whereas the suppression of mRNA expression of other genes by ARC was not reversed by the pancaspase inhibitor, suggesting a novel mechanism of how ARC may affect stability or expression of mcl-1 mRNA. It has been shown before that Z-VAD-FMK may protect mcl-1 mRNA downregulation by another transcriptional inhibitor staurosporine. 8 These data may suggest that downregulation of Mcl-1 mRNA expression by elongation inhibitors 1 is partially caspase dependent. As Z-VAD-FMK simultaneously protects against ARC-induced mitochondrial injury (Figure 1e ) and from downregulation of mcl-1 mRNA, apparently Mcl-1 modulates Z-VAD-FMK-directed protection from ARC-induced mitochondrial damage.
As ARC suppressed Mcl-1 leading to apoptosis in the leukemia cells, we investigated whether small molecular inhibitor of Bcl-2/Bcl-X L , ABT-737, could synergize with ARC in inducing apoptosis in these cells. We treated HL60 and U937 cells with ARC or ABT-737 alone or in combination and analyzed by two methods, that is, immunoblotting with cleaved caspase-3 and Annexin V-PE staining followed by FACS analysis. As shown in Figure 3a , treatment with 0.25 mM ARC or 0.2 mM ABT-737 alone induced very little caspase-3 cleavage in HL60 and U937 cells, whereas combined treatment with both the drugs induced significantly increased caspase-3 cleavage. The strong synergy between the two drugs in inducing apoptosis in HL60 (Figure 3b ) and U937 (Figure 3c ) cells is further confirmed by Annexin V-PE staining. Although treatment with ARC or ABT-737 alone, induced very little or no apoptosis in comparison with control, treatment with a combination of both the drugs resulted in 50-60% (relatively to control) of the cells undergoing apoptosis (Figures 3b and c) . The percentage of apoptotic cell population induced by combination treatment was 6 to 10-fold greater than the sum of apoptotic cell populations induced by single-drug treatment, showing highly synergistic killing effects of these drug combinations on Letters to the Editor human leukemia cells. Our data are similar to a previously published report in which CDK inhibitor, roscovitine, downregulated Mcl-1 and synergized with ABT-737 to induce apoptosis in human leukemia cells. 7 As CDK inhibitors usually inhibit CDK9 and global transcription, they also inhibit expression of short-lived proteins, including Mcl-1. Our results suggest that downregulation of Mcl-1 by ARC is a major contributor to its synergy with ABT-737 and that ARC has a potential to be developed as individual or combination drug against human leukemia. 14 C-labelled imatinib at the clinically relevant concentrations of 1 and 2 mM for 2 h at 37 1C, alone and in combination with the OCT-1-specific inhibitor prazosin (100 mM) and non-radiolabelled nilotinib (1 and 2 mM). We have defined OCT-1 Activity to be the functional activity of the OCT-1 protein involved in imatinib transport, and is determined by the difference between imatinib IUR in the absence and presence of prazosin. 3 As shown in Figure 1 , a reduction in the intracellular concentration of imatinib was again observed in patient cells in the presence of both 1 and 2 mM nilotinib. This failed to reach statistical significance at either 1 or 2 mM of imatinib. Importantly, there was also no statistically significant effect of either 1 or 2 mM nilotinib on the OCT-1 Activity for imatinib in this patient cohort (P ¼ 0.71 and 0.974, respectively). It is important to note that although the reductions seen in IM IUR on addition of prazosin and nilotinib in most patients and cell lines are not of enough magnitude to render the change statistically significant, these reductions occur consistently in every experiment performed. Interestingly, although also not significant statistically, the largest reduction in the IM concentration was in the 2 mM IM þ prazosin arm of the experiment, in which the nonprazosin-inhibitable, most likely, passive transport of imatinib is measured (Figure 1 ). To investigate this further, the same experiments were performed in K562 cells at both 37 1C (n ¼ 3) and 4 1C (n ¼ 4). At 37 1C the same changes were observed in the IUR of IM with the addition of nilotinib (Figure 2a) . Importantly, when these experiments were performed at 4 1C (Figure 2b 
